SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®
Phase 3
Completed
- Conditions
- DiphtheriaTetanusPertussis
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 649
- Registration Number
- NCT00258895
Safety of Imovax Polio in Chinese Infants and Children
Phase 3
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: Inactivated Poliomyelitis vaccine
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 40
- Registration Number
- NCT00258843
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
Phase 2
Completed
- Conditions
- Meningococcal InfectionMeningitis
- Interventions
- Biological: Polysaccharide Diphtheria Conjugate Vaccine
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 234
- Registration Number
- NCT00258856
Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine
Phase 4
Completed
- Conditions
- Influenza
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 120
- Registration Number
- NCT00258830
Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan
Phase 3
Completed
- Conditions
- DiphtheriaTetanusPertussis
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 115
- Registration Number
- NCT00258908
Immunogenicity Study of the Influenza Vaccine in Adults
Phase 2
Completed
- Conditions
- InfluenzaOrthomyxoviridae Infections
- Interventions
- Biological: Inactivated, split-virion, influenza virusBiological: Inactivated, split-virion influenza vaccine
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 978
- Registration Number
- NCT00258934
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
Completed
- Conditions
- Pertussis
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 327293
- Registration Number
- NCT00258882
Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza Virus Vaccine (Fluzone®)
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 30
- Registration Number
- NCT00258817
Safety and Immune Response of Different Pediatric Combination Vaccines.
Phase 3
Completed
- Conditions
- DiphtheriaPertussisPolio
- Interventions
- Biological: DTaP-IPV and ActHIB®Biological: DAPTACEL®. (DTaP), IPOL®., and ActHIB®.
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 2167
- Registration Number
- NCT00255047
Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine
Completed
- Conditions
- Meningococcal DiseaseMeningitis
- Interventions
- Biological: None administered in this study
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 62626
- Registration Number
- NCT00254995
© Copyright 2025. All Rights Reserved by MedPath